OCUMENSION THERAPEUTICS |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.94 HKD | -0.14% |
|
+2.21% | +3.89% |
| Apr. 15 | Ocumension Therapeutics Completes Phase III Trials for Postoperative Inflammation Drug | MT |
| Apr. 15 | Ocumension Therapeutics Announces Phase III Clinical Trial of OT-502 in China | CI |
Evolution of the average Target Price on Ocumension Therapeutics
Price target over the last 5 years
History of analyst recommendation changes
606a6b0984fc8e67b13fc93d6e123.PDyOU-SAKp9QPuP14nKFVp9INoOj6IAPmOxn7GzdsMM.c2v7K5T1Xcs8XIiym0XtMdg5WMLX0bNXyKUhgw2P0YJTf8c019p77QNqkA~a602ca60d5bb7b92c3e70b9bf955b0f7
Analysts' Consensus
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
6.424
CNY
Average target price
8.653
CNY
Spread / Average Target
+34.69%
High Price Target
11.32
CNY
Spread / Highest target
+76.25%
Low Price Target
6.47
CNY
Spread / Lowest Target
+0.71%
Consensus detail
Consensus revision (last 18 months)
Analysts covering Ocumension Therapeutics
| UBS |
Trading Rating
Investor Rating
ESG Refinitiv
EPS Revisions
- Stock Market
- Equities
- 1477 Stock
- Consensus Ocumension Therapeutics
